Table 1. Pharmacokinetic parameters following a single dose of long-acting i.m. fulvestrant 250 mg in healthy female postmenopausal volunteers (AstraZeneca, data on file) and in postmenopausal women with advanced breast cancer (Trial 0020, Robertson et al, 2003a).

	Healthy volunteers	Breast cancer patients (study 0020)
AUC(0–28) (ng ml−1) gmean (CV, %)	176 (34.5) (n=10)	148 (45.3) (n=13)
Cmax (ng ml−1) gmean (CV, %)	11.4 (44.8) (n=10)	8.20 (63.8) (n=16)
tmax (h) median	144.0 (n=10)	167.3 (n=15)
Cmin (ng ml−1) gmean (CV, %)	2.6 (25.2) (n=10)	2.62 (33.4) (n=14)

gmean=geometric mean; SD=standard deviation; CV=coefficient of variation; AUC_(0–28)= area under the plasma concentration–time curve from 0 to 28 days; C_max=maximum plasma concentration; t_max=time to C_max; C_min=minimum plasma concentration.